Clinical trials: Eosinophils
Asthma
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils…
- Trial name
- NCT02452190
- Testing
- Reslizumab
- Where
- 226 sites in United States, Argentina and 19 more
- Volunteers
- 468 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.